224 related articles for article (PubMed ID: 8842136)
1. Resistant hypertension: an overview.
McAlister FA; Lewanczuk RZ; Teo KK
Can J Cardiol; 1996 Sep; 12(9):822-8. PubMed ID: 8842136
[TBL] [Abstract][Full Text] [Related]
2. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
3. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
4. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
5. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenergic antagonists in hypertension: a review of the evidence.
Warmack TS; Estes MA; Heldenbrand S; Franks AM
Ann Pharmacother; 2009 Dec; 43(12):2031-43. PubMed ID: 19934392
[TBL] [Abstract][Full Text] [Related]
7. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
[TBL] [Abstract][Full Text] [Related]
8. The 2000 Canadian recommendations for the management of hypertension: Part one--therapy.
McAlister FA; Levine M; Zarnke KB; Campbell N; Lewanczuk R; Leenen F; Rabkin S; Wright JM; Stone J; Feldman RD; Lebel M; Honos G; Fodor G; Burgess E; Tobe S; Hamet P; Herman R; Irvine J; Culleton B; Petrella R; Touyz R;
Can J Cardiol; 2001 May; 17(5):543-59. PubMed ID: 11381277
[TBL] [Abstract][Full Text] [Related]
9. Resistant hypertension: an overview of evaluation and treatment.
Sarafidis PA; Bakris GL
J Am Coll Cardiol; 2008 Nov; 52(22):1749-57. PubMed ID: 19022154
[TBL] [Abstract][Full Text] [Related]
10. Current options for the treatment of resistant hypertension.
Ahmed MI; Pisoni R; Calhoun DA
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1385-93. PubMed ID: 19900021
[TBL] [Abstract][Full Text] [Related]
11. Resistant hypertension: diagnosis and management.
Papadopoulos DP; Papademetriou V
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):113-8. PubMed ID: 16891288
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
13. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment.
Acelajado MC; Calhoun DA
Cardiol Clin; 2010 Nov; 28(4):639-54. PubMed ID: 20937447
[TBL] [Abstract][Full Text] [Related]
14. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
15. [Refractory arterial hypertension--where is the refractoriness? Hic rhodus, hic salta!].
Jelaković B; Laganović M; Kuzmanić D
Lijec Vjesn; 2001; 123(7-8):184-90. PubMed ID: 11729614
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
17. The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy.
McAlister FA; Zarnke KB; Campbell NR; Feldman RD; Levine M; Mahon J; Grover SA; Lewanczuk R; Leenen F; Tobe S; Lebel M; Stone J; Schiffrin EL; Rabkin SW; Ogilvie RI; Larochelle P; Jones C; Honos G; Fodor G; Burgess E; Hamet P; Herman R; Irvine J; Culleton B; Wright JM;
Can J Cardiol; 2002 Jun; 18(6):625-41. PubMed ID: 12107420
[TBL] [Abstract][Full Text] [Related]
18. Resistant hypertension: what to do after trying 'the usual'.
Kaplan NM
Geriatrics; 1995 May; 50(5):24-5, 29-30; 33 passim. PubMed ID: 7737525
[TBL] [Abstract][Full Text] [Related]
19. Reduction of blood pressure in patients with treatment-resistant hypertension.
Acelajado MC; Calhoun DA; Oparil S
Expert Opin Pharmacother; 2009 Dec; 10(18):2959-71. PubMed ID: 19925047
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol: a third-generation beta-blocker for hypertension.
Cheng JW
Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
